In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy targeted capital to harvest the long-term cash flows generated by those same drugs. A prime example unfolded when Royalty Pharma plc (NASDAQ:RPRX) acquired a portion of Neurimmune's royalty interest in AstraZeneca PLC (NYSE:AZN) candidate cliramitug.
Royalty Pharma agreed to pay Neurimmune up to $425 million, starting with $125 million upfront, in exchange for a 3% to 4% royalty on global net sales. In the first quarter of 2027, Royalty Pharma will pay another $125 million in cash, with the remaining $175 million tied to clinical and regulatory milestones. Cliramitug is currently in the Phase 3 DepleTTR-CM trial, with data readouts expected in 2028.
It represents a unique therapeutic approach to transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a fatal condition caused by misfolded protein accumulation in the heart. Current approved treatments only slow progression by preventing new amyloid build-up. Cliramitug, by contrast, is a TTR-fibril-depleting antibody designed to actually clear existing deposits.
This distinction positions the asset as a high-reward addition to AstraZeneca's rare disease footprint and a strong cash-flow generator for Royalty Pharma if Phase 3 succeeds. When comparing performance, we must note an accounting mismatch: AstraZeneca PLC recently reported its Q2 and H1 2026 results, whereas Royalty Pharma plc's most recent report covers Q1 2026 (its Q2 earnings have not been released yet). Comparing a Q1 period directly against a Q2 period isn't apple-to-apples, but reviewing their financial trajectories shows both companies executing well in their respective models.
AstraZeneca PLC continues to run at scale. In H1 2026, total revenue rose 6%, propelled by double-digit expansion across Oncology and Rare Disease. This growth helped offset headwinds from loss of exclusivity on Farxiga in the U.S. and price pressures in China.
Core operating profit and Core EPS both advanced by 11%, demonstrating solid operating leverage. The company's management reconfirmed full-year 2026 guidance and increased the interim dividend by 3 cents to $1.06 per share. CEO Pascal Soriot pointed out that six Phase 3 readouts hit positively in the first half.
Extract — continue reading at the source.
